short acting glp 1 agonists Frontiers GLP-1 Agonists are commonly used
Description
Exercise, especially resistance training, is strongly encouraged while on GLP-1 medications
It is estimated that upwards of 30 million Americans will be on GLP-1 treatment in 2030 (an increase of 10 million from those on branded GLP-1s in 2026), making the growth of GLP-1s one of the key storylines to watch in the new year
What raises concerns are some of the recent reports of serious ADRs associated with GLP-1RAs: (i) Pfizers disclosure of elevated aminotransferases in users of lotiglipron (a novel oral GLP-1RA) is indicative of hepatocellular injury [11]
10.1152/physrev.00013.2014 Physiol Rev
